Arcalyst (rilonacept) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The arcalyst (rilonacept) market size has grown strongly in recent years. It will grow from $0.24 million in 2025 to $0.26 million in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to identification of il 1 driven diseases, limited alternatives for rare inflammatory conditions, strong clinical outcomes with rilonacept, regulatory approvals for orphan indications, specialist adoption of biologic therapies.

The arcalyst (rilonacept) market size is expected to see strong growth in the next few years. It will grow to $0.33 million in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to growing diagnosis of autoinflammatory syndromes, expansion into additional indications, improved genetic screening, increased biologic therapy accessibility, rising investment in rare disease treatments. Major trends in the forecast period include rising adoption of il 1 blocking therapies, growing use in rare autoinflammatory disorders, expansion of long term inflammation control treatments, increased focus on targeted cytokine inhibition, improved disease management for chronic inflammatory conditions.

The growing demand for personalized medicines is expected to propel the growth of the Arcalyst (rilonacept) market going forward. Personalized medicine is a healthcare approach that customizes treatment and clinical decisions based on an individual’s genetic makeup, environment, and lifestyle. The demand for personalized medicine is increasing due to its ability to enhance treatment efficacy, minimize adverse effects, and address patient-specific differences in disease progression and drug response. As personalized medicine gains wider adoption, improved diagnostic tools and heightened awareness are enabling better identification of rare and genetically driven conditions. This, in turn, leads to a higher number of patients being diagnosed with conditions that can be treated with Arcalyst, thereby increasing demand for the drug. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Additionally, in February 2023, PMC reported that the FDA approved 12 new personalized medicines in 2022, marking the eighth consecutive year in which personalized medicines accounted for at least one-quarter of all new drug approvals. Therefore, the rising demand for personalized medicine is driving the growth of the Arcalyst (rilonacept) market.

Major companies operating in the Arcalyst (rilonacept) market are concentrating on expanding indications, such as the use of interleukin-1 (IL-1) trap therapy for recurrent pericarditis, to strengthen their competitive position. Interleukin-1 trap therapy works by blocking excessive IL-1 proteins, thereby reducing harmful inflammation in the body. For instance, in May 2024, Kiniksa Pharmaceuticals, a US-based biopharmaceutical company, received FDA approval for Arcalyst in the treatment of recurrent pericarditis. The approval includes features such as weekly subcutaneous dosing, dual IL-1α and IL-1β inhibition, and a favorable long-term safety profile. This indication expansion significantly broadens Arcalyst’s target patient population beyond its initial use in Cryopyrin-Associated Periodic Syndromes (CAPS), although wider utilization may also increase exposure to competition, long-term safety evaluation, and payer scrutiny.

In August 2023, Fairmount Funds Management LLC, a South Philadelphia-based investment firm, acquired a stake in Kiniksa Pharmaceuticals for an undisclosed amount. This investment aligns with Fairmount’s long-term strategy of generating value within the biotechnology sector. Kiniksa Pharmaceuticals is a Bermuda-based company that manufactures Arcalyst (rilonacept).

Major companies operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.

North America was the largest region in the arcalyst (rilonacept) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arcalyst (rilonacept) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the arcalyst (rilonacept) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the arcalyst market by increasing costs for imported biologic ingredients and injectable formulation components. These impacts are most evident in hospital and specialty pharmacy distribution channels across north america and europe. Higher tariffs have contributed to pricing pressures for orphan biologic therapies. At the same time, tariffs are encouraging localized biologic manufacturing and supply chain diversification. This supports long term treatment availability and market stability.

The arcalyst (rilonacept) market research report is one of a series of new reports that provides arcalyst (rilonacept) market statistics, including arcalyst (rilonacept) industry global market size, regional shares, competitors with a arcalyst (rilonacept) market share, detailed arcalyst (rilonacept) market segments, market trends and opportunities, and any further data you may need to thrive in the arcalyst (rilonacept) industry. This arcalyst (rilonacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Arcalyst (rilonacept) is a prescription medication categorized as an interleukin-1 (IL-1) inhibitor. It is used to treat specific inflammatory conditions that result from excessive production of interleukin-1, a protein central to the body’s inflammatory response. Rilonacept acts by binding to interleukin-1 alpha and beta, preventing their interaction with cellular receptors, which reduces inflammation and helps relieve symptoms linked to the underlying disorders.

The main forms of Arcalyst (rilonacept) include lyophilized and liquid formulations. Lyophilized Arcalyst is a freeze-dried version of rilonacept that is reconstituted before administration. The clinical indications include cryopyrin-associated periodic syndromes (CAPS), deficiency of interleukin-1 receptor antagonist (DIRA), and other conditions. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies and is used by both adult and pediatric patients.

The arcalyst (rilonacept) market consists of monoclonal antibodies, anti-inflammatory drugs, rare disease drugs and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.